glad I got your attention....haven't been wrong about the likes of #$%$ such as you though have I lowlife
affirmed....I have been noticing the change in your tune for some time now (surprisingly nonetheless)....are you still long?
With over 18 million shares shorted on this stock, what is the average cost to buy back those 18 million shares? I would guess $3.50 - $4 / share. If we take the median of $3.75 x 18 mil shares, that is almost $68mil to buy back those shares. With a market cap today of $330mil, 21% of this company is shorted. Am I figuring this correctly? If so, at what point does this become an attractive short squeeze for BIG money?
This is the first time in 2.5 years you have ever posted on this board too. Can you flocking shorts be anymore creative? What a pathetic excuse for investors you flakes are!!!
jr...there are plenty of opportunities to bring your cost basis down. Maintain a core holding and trade enough to bring cost basis down a few points each time...not like anyone is going to miss the proverbial boat. Of course at these prices, you are going to have to wait for a bump in the share price to execute. But we all know what happens after good news.... :)
Gotcha....I am watching the stock climb to $2.64 on the ask side and every time it is drained down a little, more shares are thrown at the 2.64 ask.....then all of a sudden the price drops as if a block was sold at market. I find it harder and harder to distinguish between algorithm trading and the MM manipulation. I do see where we are going 2-3 minutes without a share traded...seems very slow
If they are proceeding with litigation - NO. If they intend to negotiate - NO. ATRS is NOT known for news releases. I cannot imagine them trying to "rub it in" when it would no be beneficial...except to maybe us the shareholders...short term
Really??? There is less than 152K shares traded so far today according to my Level II screen. Just broke through 152K. Yesterday by 11:30 there was 700K.
I get the impression MANY are waiting for some news from Medac.
Someone (experienced in medical / prescription drug sales) should call Medac HR and inquire about the positions. Maybe they can get some inside info as to the anticipated start of the launch / sales
Correct....to a degree. FDA has not approved the drug in specific doses combined with the injector
This news release tells me that ATRS is confident in their decision to proceed with litigation. And that the final result if in favor of ATRS will be that Medac can go to market with the drug in specific doses that ATRS does NOT already have a patent for. That is my understanding so far.
It also negates the theory by some on this board that PW had made some serious omissions / mistakes in preparing the Otrexup launch (shorts will use any means to shake out shares) and that is the reason or part of the reason for his departure. Obviously ATRS is stnding behind everything that was put in place prior to the launch
Everyone knew they would be losing money until later this year depending on the escalation of Otrexup sales. We also know that we are exceeding expectations in revenue generated by Otrexup...or at least that is the general consensus on this board.
You are not a logical thinker are you? But then when you get paid to post from a specific view....it is no wonder all of your posts are slanted that way. Why not use your time and talents for something positive? Are you always negative with your wife and kids also...you know...take home your work and attitude. That has to be a miserable life for ALL!
Why not just post the article if you already read it?
July 10, 2014, 3:03 P.M. ET
Chinese Solar Market: Signs of Pickup?
By Dimitra DeFotis
Agence France-Presse/Getty Images
A solar power plant near New Delhi, India.
The Chinese solar market appears to be picking up after a weak first half, according to Roth Capital Partners.
Roth highlighed takeaways Chinese solar player ReneSola (SOL) after a recent San Francisco confab:
(1) SOL continues to differentiate itself by (a) having a geographically-diversified module assembly footprint with locations such as India, South Africa, Poland, Turkey, Malaysia, etc. and by (b) Focusing on downstream DG (with comprehensive supporting infrastructure, such as sales, logistics, warehouses, after-sales support, and technical support); (2) Quarterly operating expenses should remain around ~$50 million; and (3) third quarter module capacity does not appear to be fully sold out.
Roth has Buy ratings on Canadian Solar(CSIQ) and Enphase Energy (ENPH), and on Chinese players JA Solar Holdings (JASO), JinkoSolar Holding (JKS) and Trina Solar (TSL). Roth is Neutral rating on Yingli Green Energy Holding (YGE) and ReneSola. Canadian Solar is the only name that’s higher today, up 1%. The other names have all sliped, with the biggest loser being Yingli, down more than 4%. Roth is decidedly upbeat:
“We hosted a booth tour at Intersolar in San Francisco, and met with companies throughout the solar value chain. The overall mood during the meetings was upbeat and optimistic, highlighting healthy fundamentals and strong growth in the U.S. despite increasing ASPs. Many are now focused on the upcoming July 24 preliminary AD decision. The Chinese market appears to be picking up after a weak first half.”
As previously disclosed, on February 28, 2014, Antares Pharma, Inc. (“Antares”) sued Medac Pharma, Inc. (“Medac”) and its foreign parent, medac GmbH, in the United States District Court for the District of Delaware alleging infringement. Antares is asserting four patents. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to enjoin Medac from selling its methotrexate auto-pen product if and when such product is approved for sale in the United States, pending the final resolution of the litigation. Two of Antares’ asserted patents were at issue in the preliminary injunction. On July 10, 2014, the District Court denied Antares’ motion for preliminary injunction. Antares believes in the strength of its intellectual property and intends to vigorously prosecute its litigation claims. The litigation is expected to proceed to a jury trial unless settled by the parties; a trial date has not been set.
Short Interest - Nasdaq has not updated since 6/13. In fact, I have a list of 15+ stocks and none have been updated...not sure why.
Does anyone have access to real time short interest figures? Thx
And unfortunately for me, you actually need some grammar lessons. Did the same people that taught you to read, teach you to write?
Every day? It doesn't happen that frequently. But being the savvy investor you are, you would realize that is one way of bringing down cost basis when slammed with a loss. It also allows me to increase my core holdings.
So you are on here bragging about making money in SRPT....did not disclose that in your post...just popped it out there now...........attention hound?
I wasn't complaining about shorts...I was calling you out for what you truly are...feel offended? tough sheet
You made money today but obviously you already had to cover or risk losing significant money once there is resolution later today. All three of you act as if you are reeling in the bucks....by being short (though I seriously doubt you can even afford to buy $3 stocks on your gross income) but even with the Nas down 10% plus in the last week or so.....this stock is down what....6%.
You clowns (all 3...one in the same anyway) are ALL talk....you show up on days the WHOLE market is down and act like you are some sort of savvy investor. But in fact...you are just low life #$%$...scraping away at a meager existence. And having to compromise moral values your parents may have instilled in you during the process. GET A LIFE LOSERS!!! How many times have you heard that?
bg....4-5 responses and no one addressed your question. Probably because we have seen NO sales model that displays the number of scripts (Nrx or TRx) need to achieve $100mil / $200mil / $300mil from 2015 through 2017.
Some on this board will point to Ali Yasar's SA article and the sigmoid-based model which indicates we should be at $1.5mil this quarter, $3mil - Q3 and $6mil - Q4. He admits that it is a static model based on goals conveyed by ATRS management and should only be used as a comparison to actual sales.
I have laid out a model to achieve those figures mentioned above with a steadily progressive increase in NRx sales through Q4-2017 (unlike the sigmoid model which starts out slow, has a sudden and quick acceleration and then levels off). My model achieves the benchmarks mentioned above with a deduct factor of 15% / 25% / 35% each year to account for lack of refills. That model is set up with an average of 130 Nx for Q1, average of 170 Nx for Q2 (we averaged 166 Nx for that period) and it progressively increases by 40 Nx per quarter through the end of 2017. 210 Nx average is required for Q3 and we are already seeing close to 250 (though that may see a slight dip due to holiday). So in answer to your question, I would have to say we are significantly surpassing the required scripts to achieve the goals set out by management. Once again the reason for posting my numbers is because many posters were claiming $1.4 - $1.5mil per analysts and sigmoid model. Their tunes have changed recently.....we will have to see who is closest come earnings call.
Again, I use Nx and assume every new prescription will be refilled. RA is a disease that does not go away. I make adjustments for lack of 100% refills and inconsistent refills. If I am a patient and I do not need another injection for 10 days in lieu of 7 days, I am going to reduce my co-pay costs accordingly and inject myself when I need the damn injection-not when some Yahoo message board troll decides